Insider at Arcutis (NASDAQ: ARQT) files to sell 9,794 shares

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider plans stock sale under Rule 144. A holder named Patrick Burnett filed notice to sell 9,794 shares of Arcutis common stock through Merrill Lynch, with an aggregate market value of $252,748.08, on or about 02/04/2026 on the NASDAQ.

The 9,794 shares to be sold were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The filing also lists several prior open‑market sales of Arcutis common shares by the same holder over the past three months, with disclosed share amounts and gross proceeds for each transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	9794	252748.08	122492192	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			9794	02/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	02/02/2026	3675	93706.62
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/05/2025	3846	91216
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/06/2025	17250	417145
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/15/2025	11500	332851.03
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	12/31/2025	1697	49561.25
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	01/05/2026	2490	72165.7

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arcutis Biotherapeutics (ARQT) Form 144 filing disclose?

The Form 144 shows a holder, Patrick Burnett, intends to sell 9,794 Arcutis common shares. The planned sale, through Merrill Lynch on NASDAQ, has an aggregate market value of $252,748.08, based on the figures disclosed in the notice.

How many Arcutis (ARQT) shares are planned to be sold and where?

The notice covers the planned sale of 9,794 Arcutis common shares. These shares are to be sold through Merrill Lynch on the NASDAQ exchange, with the filing listing an aggregate market value of $252,748.08 for the transaction.

When were the Arcutis (ARQT) shares to be sold under Form 144 acquired?

The 9,794 Arcutis common shares were acquired on 02/01/2026. They were received through a restricted stock vesting transaction from Arcutis Biotherapeutics, as disclosed in the acquisition section of the Form 144 notice.

What approximate sale date is disclosed in the Arcutis (ARQT) Form 144?

The filing lists an approximate sale date of 02/04/2026 for the 9,794 shares. This date appears in the securities information table, which also identifies NASDAQ as the exchange where the common stock is expected to be sold.

Does the Arcutis (ARQT) Form 144 mention recent prior stock sales?

Yes. The notice lists several prior sales of Arcutis common shares by Patrick Burnett over the past three months, including transactions on 11/05/2025, 11/06/2025, 12/15/2025, 12/31/2025, 01/05/2026, and 02/02/2026, each with specific share counts and gross proceeds.

How many Arcutis (ARQT) shares are shown as outstanding in the filing?

The securities table reports 122,492,192 Arcutis common shares outstanding. This figure provides a reference for the company’s total common stock base relative to the 9,794 shares covered by the Form 144 notice.